Neoplasms Clinical Trials in Canada

A listing of 18 Neoplasms clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Neoplasms

1 - 12 of 18

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 18 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Neoplasms participants are .

SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases

NCT03694015

Recruiting

The primary objective is to patient-reported Quality of Life related to complete control of Radiation Induced Nausea and Vomiting (RINV) between standard palliative radiotherapy and VMAT. Secondarily, we will assess rate of complete control of RINV. However, the investigators hypothesize that there will be no difference in pain response between the two arms, because they are receiving the same dose.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/19/2025

Locations: BC Cancer, Prince George, British Columbia +4 locations

Conditions: Neoplasm Metastasis, Neoplastic Processes, Neoplasms, Pathologic Processes

Learn More ›

Collection of Tissue Samples for Cancer Research

NCT00900198

Recruiting

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. * To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Eligibility: -Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites. Design: * This is a multicenter tissue procurement protocol with NCI as the coordinating center. * For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol. * For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits. * Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture. * This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models. * Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first. Read Less

Gender:

ALL

Ages:

2 months and above

Trial Updated:

08/13/2025

Locations: UC Davis, Sacramento, California +16 locations

Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157

Recruiting

The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: City of Hope, Duarte, California +21 locations

Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis

Learn More ›

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

NCT04260802

Recruiting

This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/11/2025

Locations: Cross Cancer Institute, Edmonton, Alberta +4 locations

Conditions: Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer

Learn More ›

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626

Recruiting

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: Loma Linda University Cancer Center, Loma Linda, California +31 locations

Loma Linda University Cancer Center, Loma Linda, California

UC Davis Comprehensive Cancer Center, Sacramento, California

Sarah Cannon Research Institute at HealthONE, Denver, Colorado

AdventHealth Celebration, Celebration, Florida

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida

The University of Kansas Cancer Center, Kansas City, Kansas

National Institutes of Health, Bethesda, Maryland

Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

Memorial Sloan-Kettering Cancer Center, New York, New York

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, Oklahoma

Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville, Tennessee

The University of Texas, MD Anderson Cancer Center, Houston, Texas

UT Health Mays Cancer Center, San Antonio, Texas

Fred Hutchinson Cancer Center, Seattle, Washington

University of Wisconsin- Madison, Madison, Wisconsin

Princess Margaret Cancer Centre, Toronto, Ontario

Research Institute of McGill University Health Centre, Montreal, Quebec

Institut Bergonié, Bordeaux, Not set

Centre Leon Berard, Lyon, Not set

Hopsital Institut Curie, Paris, Not set

Oncopole Claudius Regaud IUCT, Toulouse, Not set

Institute Gustave Roussy, Villejuif, Not set

Vall d'Hebron Institute of Oncology, Barcelona, Cataluna

Clinica Universidad de Navarra, San Blas-Canillejas, Madrid

NEXT Oncology Barcelona, Hospital Quirónsalud Barcelona, Barcelona, Not set

START Madrid FJD, Madrid, Not set

Hospital Universitario Quirónsalud Madrid, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Instituto de Investigacion Sanitaria, INCLIVA, Valencia, Not set

Conditions: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm

Learn More ›

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796

Recruiting

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Gender:

ALL

Ages:

All

Trial Updated:

06/24/2025

Locations: University of Alabama Birmingham, Birmingham, Alabama +181 locations

University of Alabama Birmingham, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic Phoenix, Phoenix, Arizona

Arizona Cancer Center, Scottsdale, Arizona

Local Institution - 01021, Tucson, Arizona

City Of Hope, Duarte, California

University Of California San Diego Moores Cancer Center, La Jolla, California

Local Institution - 01206, Los Angeles, California

Local Institution - 01043, Sacramento, California

University of California, San Francisco- California, San Francisco, California

UCLA Medical Centre-Santa Monica, Santa Monica, California

Stanford Cancer Center, Stanford, California

University Of Colorado Cancer Center, Aurora, Colorado

Colorado Blood Cancer Institute, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

Local Institution - 01050, Washington, District of Columbia

The Mayo Clinic - Jacksonville, Davis-E, Jacksonville, Florida

Baptist Cancer Center, Miami, Florida

Local Institution - 01035, Orlando, Florida

H. Lee Moffitt Cancer Center and Research Institute University of South Florida, Tampa, Florida

Winship Cancer Institute of Emory University, Atlanta, Georgia

Northside Hospital, Inc, Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

University Of Chicago Medical Center, Chicago, Illinois

Local Institution - 01040, Maywood, Illinois

Local Institution - 01063, Niles, Illinois

IN Univ Simon Cancer Center, Indianapolis, Indiana

Local Institution - 01020, Indianapolis, Indiana

Kansas University Medical Center, Westwood, Kansas

Cancer Center of Kansas, Wichita, Kansas

University Of Kentucky, Lexington, Kentucky

Norton Cancer Institute Louisville Oncology, Louisville, Kentucky

Local Institution - 01026, New Orleans, Louisiana

University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Sidney Kimmel Comp Cancer Center at Johns Hopkins, Baltimore, Maryland

National Cancer Institute, Bethesda, Maryland

Local Institution - 01107, Boston, Massachusetts

Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston, Massachusetts

Local Institution - 01106, Boston, Massachusetts

University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Karmanos Cancer Center Wayne State University, Detroit, Michigan

Providence Cancer Institute, Southfield, Michigan

M Health Fairview University of Minnesota Medical Center - East Bank, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Siteman Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 01030, East Brunswick, New Jersey

Hackensack University Medical Center, Hackensack, New Jersey

Morristown Memorial Hosp, Morristown, New Jersey

Local Institution - 01053, New Brunswick, New Jersey

New York Oncology Hematology P.C., Albany, New York

Roswell Park Cancer Institute, Buffalo, New York

Local Institution - 01066, New York, New York

Weill Cornell Medicine / New York Presbyterian Hospital, New York, New York

Icahn School Of Medicine At Mount Sinai, New York, New York

Columbia University Medical Center/New York-Presbyterian Hospital, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Local Institution - 01051, Rochester, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Novant Health, Salisbury, North Carolina

Oncology Hematology Care, Inc., Cincinnati, Ohio

University Hospitals of Cleveland, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Local Institution - 01074, Columbus, Ohio

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma

Willamette Valley Cancer Institute, Eugene, Oregon

Providence Portland Medical Center, Portland, Oregon

Oregon Health and Science University OHSU, Portland, Oregon

Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia, Pennsylvania

University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

UPMC Cancer Pavillion, Pittsburgh, Pennsylvania

Hematology and Oncology Associates of SC, LLC, Greenville, South Carolina

Local Institution - 01064, Sioux Falls, South Dakota

Sarah Cannon Research Inst, Nashville, Tennessee

Texas Oncology, Dallas, Texas

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

UT Southwestern Medical Center, Dallas, Texas

University of Texas- MD Anderson, Houston, Texas

Sam Clinical Research Center, San Antonio, Texas

Local Institution - 01033, Temple, Texas

Texas Oncology, P.A. - Tyler, Tyler, Texas

University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah

Intermountain Healthcare - LDS Hospital, Salt Lake City, Utah

University Of Virginia Health System, Charlottesville, Virginia

Local Institution - 01045, Norfolk, Virginia

Local Institution - 01023, Richmond, Virginia

Swedish Cancer Institute, Seattle, Washington

Local Institution - 01060, Seattle, Washington

Fred Hutchinson Cancer Center, Seattle, Washington

Local Institution - 01055, Tacoma, Washington

University Of Wisconsin, Madison, Wisconsin

Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin

Local Institution - 01069, Wauwatosa, Wisconsin

Peter MacCallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Allgemeinen Krankenhaus (AKH) Wien - Medizinische Universitaet Wien, Wien, Not set

Jules Bordet Institut, Anderlecht, Not set

Universitair Ziekenhuis Brussel, Brussel, Not set

Local Institution - 05200, Gent, Not set

Uz Gent, Gent, Not set

University Hospital Leuven, Leuven, Not set

Local Institution - UNK 2, Leuven, Not set

University Of Calgary, Calgary, Alberta

Local Institution - 02802, Vancouver, British Columbia

Local Institution - 02801, Hamilton, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

CIUSSS de l'Est-de-l'Ile-de-Montreal, Montreal, Quebec

Helsinki University Central Hospital (HUCH), Helsinki, Not set

Hopital Henri Mondor, Creteil-Paris, Not set

CHRU de Lille France, Lille Cedex, Not set

Local Institution - 09601, Lyon, Not set

Local Institution - 09400, Marseille Cedex 9, Not set

Local Institution - 09602, Marseille Cedex 9, Not set

CHU Montpellier - Hôpital Saint Eloi, Montpellier CEDEX 5, Not set

Chu Hotel Dieu, Nantes Cedex 01, Not set

Hopital Saint Louis, Paris, Not set

Hospital Saint Louis, Paris, Not set

Local Institution - 09600, Paris, Not set

Centre Hospitalier Universitaire (CHU) de Bordeaux - Hopital Haut-Leveque, Pessac, Not set

Centre Hospitalier Lyon-Sud, Pierre-Benite CEDEX, Not set

CHU La Miletrie, Poitiers Cedex, Not set

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse CEDEX 9, Not set

Gustave Roussy, Villejuif, Not set

Robert-Rossle-Klinik im HELIOS Klinikum Berlin-Buch Klinik fur Hamatologie, Onkologie u. Tumorimmuno, Berlin, Not set

Local Institution - 03155, Berlin, Not set

Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Not set

Local Institution - 03513, Dusseldorf, Not set

Local Institution - 03500, Frankfurt, Not set

Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Kinikum der Universitaeat zu Koeln, Koeln, Not set

Local Institution - 03454, Muenster, Not set

LMU Klinikum der Universität, München, Not set

Local Institution - 03503, Tuebingen, Not set

University Hospital of Ulm, Ulm, Not set

Universitatsklinikum Wurzburg Medizinische Klinik und Poliklinik II, Würzburg, Not set

Ospedali Riuniti di Ancona, Ancona, Not set

Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi, Bologna, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set

Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Not set

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Naples, Not set

Local Institution - 07500, Roma, Not set

Ospedale Pediatrico Bambino Gesu, Rome, Not set

Istituto Clinico Humanitas, Rozzano (MI), Not set

Local Institution - 07610, Torino, Not set

Azienda Sanitaria Ospedaliera San Giovanni Battista Molinette, Turin, Not set

Hokkaido University Hospital, Sapporo-shi, Hokkaido

National Cancer Center Hospital, Chuo-ku, Tokyo

Toranomon Hospital, Minato-ku, Tokyo

Local Institution - 13202, Bunkyo-ku, Not set

Kyushu University Hospital, Fukuoka, Not set

Tokai University Hospital, Isehara City, Kanagawa, Not set

Nagoya City University Hospital, Nagoya, Not set

Osaka Metropolitan university Hospital, Osaka, Not set

Japan Red Cross Medical Center, Shibuya-ku, Not set

Jichi Medical University Hospital, Shimotsuke, Not set

Local Institution - 13804, Shinjuku City, Not set

Local Institution - 04650, Amsterdam, Not set

Erasmus Medical Center - Daniel den Hoed, Rotterdam, Not set

Local Institution - 04400, Utrecht, Not set

Oslo Universitetssykehus, Oslo, Not set

Institutul Clinic Fundeni, Bucuresti, Not set

Hospital Universitario Vall D hebron, Barcelona, Not set

Hospital Universitari Germans Trias i Pujol ICO Badalona, Barcelona, Not set

Institut Clinic de Nefrologia i Urologia - Hospital Clinic i Provincial de Barcelona, Barcelona, Not set

Hospital San Joan de Deu Barcelona, Esplugues de Llobregat, Not set

Hospital Infantil Universitario Nino Jesus, Madrid, Not set

Hospital 12 De Octubre, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Virgen Del Rocio, Sevilla, Not set

Karolinska University Hospital Huddinge, Stockholm, Not set

Inselspital Bern, Bern, Not set

Local Institution - 10850, Leeds, Not set

Kings College Hospital, London, Not set

UCL Cancer Institute, London, Not set

Christie Hospital Nhs Trust, Manchester Withington, Not set

Somers Cancer Research Building, Shirley Southampton, Not set

Conditions: Neoplasms

Learn More ›

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

NCT06431594

Recruiting

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: GSK Investigational Site, Lake Mary, Florida +46 locations

GSK Investigational Site, Lake Mary, Florida

GSK Investigational Site, Fairway, Kansas

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, Detroit, Michigan

GSK Investigational Site, Grand Rapids, Michigan

GSK Investigational Site, Nashville, Tennessee

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, West Valley City, Utah

GSK Investigational Site, Cipoletti Rio Negro, Not set

GSK Investigational Site, Ciudad de Buenos Aires, Not set

GSK Investigational Site, Rosario, Not set

GSK Investigational Site, Blacktown, New South Wales

GSK Investigational Site, Macquarie University, New South Wales

GSK Investigational Site, Leuven, Not set

GSK Investigational Site, Ottawa, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

GSK Investigational Site, Helsinki, Not set

GSK Investigational Site, Tampere, Not set

GSK Investigational Site, Lyon Cedex 08, Not set

GSK Investigational Site, Saint Herblain, Not set

GSK Investigational Site, Villejuif cedex, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Rozzano MI, Not set

GSK Investigational Site, Saitama, Not set

GSK Investigational Site, Shizuoka, Not set

GSK Investigational Site, Tokyo, Not set

GSK Investigational Site, Gyeonggi-do, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Amsterdam, Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, COrdoba, Not set

GSK Investigational Site, Girona, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Pozuelo De AlarcOn Madr, Not set

GSK Investigational Site, Stockholm, Not set

GSK Investigational Site, Uppsala, Not set

GSK Investigational Site, Cambridge, Not set

GSK Investigational Site, London, Not set

Conditions: Solid Tumors, Neoplasms

Learn More ›

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797

Recruiting

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/11/2025

Locations: UAMS, Little Rock, Arkansas +107 locations

UAMS, Little Rock, Arkansas

University of California San Diego (UCSD) - Moores Cancer Center(All), La Jolla, California

Cedars-Sinai Medical Center, Los Angeles, California

Pasadena Liver Center, Pasadena, California

California Pacific Medical Center, San Francisco, California

UCLA University of California - Los Angeles, Santa Monica, California

John Muir Clinical Research, Walnut Creek, California

University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, Colorado

Uni. Of Miami- Sylvester Cancer Centre, Miami, Florida

Florida Cancer Specialists - South, Sarasota, Florida

Florida Cancer Specialists - East, West Palm Beach, Florida

Women's Cancer Care - Covington, LA, Covington, Louisiana

University Of Mississippi Medical Center, Jackson, Mississippi

Kansas City Research Institute, Kansas City, Missouri

Montefiore Medical Center (MMC) - Jack D. Weiler Hospital, Bronx, New York

Perlmutter Cancer Center- NYU Langone Health, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

MetroHealth Medical Center, Cleveland, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

University of Oklahoma Health Science Center, Oklahoma City, Oklahoma

Medical University of South Carolina, Charleston, South Carolina

Sanford Cancer Centre, Sioux Falls, South Dakota

Tennessee Oncology, Nashville, Tennessee

Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville, Nashville, Tennessee

Mary Crowley Cancer Research, Dallas, Texas

University of Texas Southwestern Medical, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Fred Hutchinson/University of Washington Cancer Consortium, Seattle, Washington

Sunnybrook Hospital, Toronto, Ontario

CHUM, Unit for Innovative Therapies, Montreal, Quebec

McGill University Health Centre, Montreal, Quebec

Beijing Cancer Hospital, Beijing, Not set

Peking Union Medical College Hospital, Beijing, Not set

Bethune Hospital of Jilin University, Changchun, Not set

Fujian Provincial Cancer Hospital, Fuzhou, Not set

Sun Yan-sen University Cancer Center, Guangzhou, Not set

Sun Yat-Sen Memrial Hospital, Sun Yat-Sen University, Guangzhou, Not set

Cancer Hospital of Shandong First Medical University, Jinan, Not set

Yunnan Cancer Hospital, Kunming, Not set

Fudan University Cancer Center, Shanghai, Not set

The Tenth People's Hospital; Shanghai Tongji University, Shanghai, Not set

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Not set

Tianjin Cancer Hospital, Tianjin, Not set

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set

Odense University Hospital, Odense, Not set

CHU Amiens-Picardie (Hopital Sud), Amiens, Not set

CHU Bordeaux, Bordeaux, Not set

CHU Cavale Blanche, Brest, Not set

Centre François Baclesse, Caen, Not set

Centre Jean Perrin, Clermont-Ferrand, Not set

Hôpital Beaujon, Clichy, Not set

Centre Georges-François Leclerc, Dijon, Not set

Grenoble University Hospital (Centre Hospitalier Universitaire Grenoble Alpes), La Tronche, Not set

CHU de LILLE - Hôpital HURIEZ, Lille, Not set

Hepatology, Hopital de la Croix-Rousse - 103 grande rue de la Croix-Rousse, Lyon, Not set

Centre Léon Bérard, Lyon, Not set

Institut Paoli-Calmettes, Marseille, Not set

Centre Antoine Lacassagne, Nice, Not set

Institut Curie - Centre de Recherche, Paris, Not set

APHP Hospital Saint-Antoine, Paris, Not set

AP-HP Université de Paris, Port Royal, Paris, Not set

Hopital Europeen Georges-Pompidou (HEGP), Paris, Not set

Hopital de la Croix Saint-Simon, Paris, Not set

Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)(Hopitaux de Bordeaux) - Groupe hospitalier Sud - Hopital Haut-Levequ, Pessac, Not set

Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, Not set

Insitute de Cancérologie de l'Ouest - Centre René Gauducheau, Saint-Herblain, Not set

ICANs, Strasbourg, Not set

Gustave Roussy Institute (IGR), Villejuif, Not set

Clinica Oncologica AOU (Azienda Ospedaliero Universitaria) delle Marche, Ancona, Not set

Istituto Clinico Humanitas, Rozzano, Milan, Not set

Fondazione Policlinico Gemelli IRCCS, Rome, Not set

Eisai Trial Site #5, Nagoya, Aichi

Eisai Trial Site #11, Toyoake, Aichi

Eisai Trial Site #2, Kashiwa, Chiba

Eisai Trial Site #8, Matsuyama, Ehime

Eisai Trial Site #7, Kurume, Fukuoka

Eisai site #13, Akashi, Hyogo

Eisai Trial Site #10, Kawasaki, Kanagawa

Eisai Trial Site #12, Kamigyo-ku, Kyoto

Eisai Trial Site #3, Osakasayama, Osaka

Eisai Trial Site #9, Hidaka, Saitama

Eisai Trial Site #1, Chuo-Ku, Tokyo

Eisai Trial Site #6, Koto-ku, Tokyo

Eisai Site 15, Minato-ku, Tokyo

Eisai Trial Site #4, Chiba, Not set

Eisai site #14, Niigata, Not set

Eisai Trial Site #1, Seongnamsi Bundang, Gyeonggi-Do

National Cancer Center, Goyang-si Gyeonggi-do, Ilsandong-gu

Korea University Guro Hospital, Guro-gu, Seoul

Eisai Trial Site #5, Jongno-gu, Seoul

Seoul National University Hospital, Jongno-gu, Seoul

Seoul St. Mary's Hospital, Seocho-Gu, Seoul

Eisai Trial Site #2, Seodaemun, Seoul

Asan Medical Centre, Songpa-Gu, Seoul

Eisai Trial Site #4, Songpa-gu, Seoul

Eisai Trial Site #3, Seoul, Not set

H. Clinico San Carlos, San Carlos, Madrid

Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (VHIO), Barcelona, Not set

University Hospital A Coruña, Coruna, Not set

Hospital Universitario de Jaén, Jaen, Not set

Clínica Universidad de Navarra, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Chang Gung Medical Foundation - Kaohsiung Branch, Kao-Hsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Chang Gung Medical Foundation - Linkou Branch, Taoyuan, Not set

Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Learn More ›

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

NCT06077877

Recruiting

The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/03/2025

Locations: GSK Investigational Site, San Francisco, California +8 locations

Conditions: Neoplasms

Learn More ›

A Study of GSK5764227 in Participants With Advanced Solid Tumors

NCT06551142

Recruiting

The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/13/2025

Locations: GSK Investigational Site, Denver, Colorado +13 locations

Conditions: Neoplasms

Learn More ›

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284

Recruiting

This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/28/2025

Locations: GSK Investigational Site, Birmingham, Alabama +129 locations

GSK Investigational Site, Birmingham, Alabama

GSK Investigational Site, Goodyear, Arizona

GSK Investigational Site, Scottsdale, Arizona

GSK Investigational Site, Fayetteville, Arkansas

GSK Investigational Site, Encinitas, California

GSK Investigational Site, La Jolla, California

GSK Investigational Site, Los Angeles, California

GSK Investigational Site, Newport Beach, California

GSK Investigational Site, San Francisco, California

GSK Investigational Site, San Marcos, California

GSK Investigational Site, Santa Monica, California

GSK Investigational Site, Washington, District of Columbia

GSK Investigational Site, Miami, Florida

GSK Investigational Site, Tampa, Florida

GSK Investigational Site, Augusta, Georgia

GSK Investigational Site, Chicago, Illinois

GSK Investigational Site, Fairway, Kansas

GSK Investigational Site, Scarborough, Maine

GSK Investigational Site, Baltimore, Maryland

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, Detroit, Michigan

GSK Investigational Site, Kansas City, Missouri

GSK Investigational Site, Farmington, New Mexico

GSK Investigational Site, Albany, New York

GSK Investigational Site, Brooklyn, New York

GSK Investigational Site, Jamaica, New York

GSK Investigational Site, New York, New York

GSK Investigational Site, Charlotte, North Carolina

GSK Investigational Site, Cleveland, Ohio

GSK Investigational Site, Columbus, Ohio

GSK Investigational Site, Hilliard, Ohio

GSK Investigational Site, Oklahoma City, Oklahoma

GSK Investigational Site, Philadelphia, Pennsylvania

GSK Investigational Site, Providence, Rhode Island

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, San Antonio, Texas

GSK Investigational Site, Salt Lake City, Utah

GSK Investigational Site, Charlottesville, Virginia

GSK Investigational Site, Seattle, Washington

GSK Investigational Site, Spokane, Washington

GSK Investigational Site, Milwaukee, Wisconsin

GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Not set

GSK Investigational Site, Cordoba, Not set

GSK Investigational Site, Barretos, Not set

GSK Investigational Site, Porto Alegre, Not set

GSK Investigational Site, Ribeirao Preto, Not set

GSK Investigational Site, Rio de Janeiro, Not set

GSK Investigational Site, Sao Jose Do Rio Preto, Not set

GSK Investigational Site, Sao Paulo, Not set

GSK Investigational Site, SAo Paulo, Not set

GSK Investigational Site, Calgary, Alberta

GSK Investigational Site, Edmonton, Alberta

GSK Investigational Site, Kelowna, British Columbia

GSK Investigational Site, Vancouver, British Columbia

GSK Investigational Site, Hamilton, Ontario

GSK Investigational Site, London, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

GSK Investigational Site, Horovice, Not set

GSK Investigational Site, Zlin, Not set

GSK Investigational Site, Copenhagen, Not set

GSK Investigational Site, Odense C, Not set

GSK Investigational Site, Bordeaux, Not set

GSK Investigational Site, Caen Cedex 5, Not set

GSK Investigational Site, Lille, Not set

GSK Investigational Site, Marseille, Not set

GSK Investigational Site, Paris, Not set

GSK Investigational Site, Saint-Herblain cedex, Not set

GSK Investigational Site, Villejuif Cedex, Not set

GSK Investigational Site, Milano, Not set

GSK Investigational Site, Modena, Not set

GSK Investigational Site, Naples, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Verona, Not set

GSK Investigational Site, Gwangju, Not set

GSK Investigational Site, Seongnam-si Gyeonggi-do, Not set

GSK Investigational Site, Seongnam-si, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Monterrey, Not set

GSK Investigational Site, Gdynia, Not set

GSK Investigational Site, Lublin, Not set

GSK Investigational Site, Olsztyn, Not set

GSK Investigational Site, Torun, Not set

GSK Investigational Site, Warszawa, Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, Girona, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Malaga, Not set

GSK Investigational Site, Murcia, Not set

GSK Investigational Site, Pamplona, Not set

GSK Investigational Site, Santander, Not set

GSK Investigational Site, Santiago de Compostela, Not set

GSK Investigational Site, Sevilla, Not set

GSK Investigational Site, Valencia, Not set

GSK Investigational Site, Zaragoza, Not set

GSK Investigational Site, Aberdeen, Not set

GSK Investigational Site, London, Not set

GSK Investigational Site, Manchester, Not set

GSK Investigational Site, Newcastle Upon Tyne, Not set

GSK Investigational Site, Oxford, Not set

GSK Investigational Site, Sutton, Not set

Conditions: Neoplasms

Learn More ›

Pediatric Early Rehabilitation in Acute Lymphoblastic Leukemia

NCT06170385

Recruiting

The purpose of this study is to determine the feasibility and acceptability of a hybrid in-person and virtual individualized physiotherapy program using the Healthy Eating and Active Living (HEAL-ME) online platform for children diagnosed with acute lymphoblastic leukemia. We would like to know if this type of hybrid program delivery model is feasible, and if children and their parents are willing and able to participate in the program. We will do this by recording how many, and what type of phy... Read More

Gender:

ALL

Ages:

Between 4 years and 17 years

Trial Updated:

01/28/2025

Locations: University of Alberta, Edmonton, Alberta

Conditions: Neoplasms, Pediatric Cancer, Physical Therapy, Telemedicine

Learn More ›

1 - 12 of 18